Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis

摘要

Omalizumab is a recombinant humanized monoclonal antibody that blocks the binding of IgE to the FceRI receptor on the surface of mast cells (MCs) and basophils, reducing receptor expression1 and the release of mediators.2 It is approved for patients 12 years or older with moderate to severe persistent allergic asthma that is inadequately controlled with inhaled corticosteroids. However, successful anti-IgE therapy with omalizumab has been documented in some conditions, such as chronic urticaria,3 idiopathic anaphylaxis,4 and mastocytosis,5 among others.